

Redefining successful primary PCI

Peter J. McCartney^{1,2} and Colin Berry^{1,2*}

¹British Heart Foundation Glasgow Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences, 126 University Place, University of Glasgow, Glasgow G12 8TA, UK; and ²West of Scotland Heart and Lung Centre, Golden Jubilee National Hospital, Glasgow, UK

Online publish-ahead-of-print 21 November 2018

This editorial refers to ‘Intramycardial hemorrhage and prognosis after ST-elevation myocardial infarction’ by S.J. Reinstadler et al., pp. 138–146.

Restoration of coronary blood flow with primary percutaneous coronary intervention (PCI) is an effective treatment for ST-segment elevation myocardial infarction (STEMI), and primary PCI is the evidence-based standard of care for STEMI patients presenting within 12 h of symptom onset.¹ On the other hand, restoration of epicardial blood flow results in reperfusion injury with failed myocardial perfusion in approximately 50% of patients,² typically in the context of a successful primary PCI procedure. Procedure success defined as normal antegrade coronary blood flow is achieved in >95% of patients during daily practice.^{3,4}

Failed myocardial reperfusion is a complex, heterogeneous microvascular problem. Several mechanisms have been implicated, including intra-vascular problems, such as distal embolization of thrombus/atheroma and extravascular problems, such as extrinsic microvascular compression due to intracellular (e.g. cardiomyocyte) and extracellular oedema.⁵ Taken together, these pathologies manifest clinically as microvascular obstruction (MVO).

Endothelial cells may be more resistant to ischaemia than the cardiac myocyte,⁶ but eventually sustained ischaemia leads to endothelial dysfunction. Endothelial damage leads to impaired capillary integrity, tissue oedema and extravasation of red blood cells into the extracellular space. Multiple studies have shown that MVO and intramycardial haemorrhage (IMH) are closely related. In general, IMH does not occur in the absence of MVO but, on the other hand, MVO commonly occurs in the absence of IMH.² The dynamic nature of MVO supports the concept that it may be reversible and thus a therapeutic target. On the other hand, IMH is a downstream pathological consequence of irreversible microvascular damage.⁷ The occurrence of IMH therefore represents failed myocardial reperfusion, and a failure of the therapeutic strategy.

MVO is a predictor of poor outcome independent of infarct size.⁸ Patients with MVO are more likely to develop heart failure post-MI with increased mortality. The prognostic significance of IMH has been the subject of much debate. In a study of 286 patients presenting with acute STEMI, we found that myocardial haemorrhage (identified by

T2* imaging) was more closely associated with all-cause death and heart failure during 2.3 years follow-up when compared with MVO alone.²

The pathophysiological mechanisms linking IMH with worse outcomes independent of infarct size and MVO are incompletely understood. Key to this may be persistent local tissue inflammation within the infarct core in response to persistence of haemoglobin breakdown products and accumulation of deoxygenated iron residues and tissue fibrosis. These pathologies prevent the natural healing process that otherwise would normally occur in reperfused myocardium in the absence of MVO and IMH. Cigarette smoking and a history of hypertension are risk factors for IMH. Carberry et al. demonstrated that persistent iron affected one in five patients who survived through to 6 months post-STEMI and was associated with adverse LV remodelling, worsening ejection fractions at 6 months. Systemic inflammation at baseline, reflected by the neutrophil count, was a univariable associate of persistent iron at 6 months, and presenting heart rate and a history of hypertension were multivariable associates.⁹ Additionally, iron deposition within the infarcted myocardium may have deleterious effects on the electrical stability of the heart and so may increase the likelihood of compromising ventricular arrhythmias and sudden cardiac death post-MI.¹⁰

Cardiovascular magnetic resonance (CMR) is the only method available to clinicians to detect this problem *in vivo*. T2* imaging is generally accepted as the reference method for the assessment of IMH in STEMI patients,¹¹ and T2* imaging is increasingly available as an option in standard CMR protocols. Blood degradation products such as deoxyhaemoglobin exert a paramagnetic effect, reducing the T2* signal, represented by hypointense areas within the infarct core. Still, local signal loss due to artefact can complicate the imaging read-out, especially if supporting features such as reduced wall motion and infarction are absent.

Reinstadler et al.¹² provide additional evidence for the clinical importance of IMH characterized by T2* imaging post-STEMI. They conducted a prospective multicentre study of 264 STEMI patients presenting within 12 h of symptom onset undergoing primary PCI. The primary endpoint was a composite of death, reinfarction, and new congestive heart failure at 12 months. Sixty patients had IMH, of these, 9 (15%) had major adverse cardiac events (MACE), whereas

The opinions expressed in this article are not necessarily those of the Editors of *EHJCI*, the European Heart Rhythm Association or the European Society of Cardiology.

* Corresponding author. Tel: +44 0141 3303325; Fax: +44 (0) 141 330 6794. E-mail: colin.berry@glasgow.ac.uk

© The Author(s) 2018. Published by Oxford University Press on behalf of the European Society of Cardiology.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

only 10 (4.9%) patients without IMH experienced a MACE. IMH was independently associated with MACE, and IMH increased the prognostic value of a model which included MVO. This study adds to the previous work by Carrick *et al.*,² reaffirming IMH as a determinative pathological complication post-STEMI.

The study by Reinstadler *et al.*¹² did have some limitations. The number of MACE events ($n=19$) was modest and in isolation the results have qualified significance. On the other hand, these data are consistent with other studies.^{2,13} Reinstadler *et al.* highlighted five patients with IMH but no MVO which is not consistent with previous studies. In a serial imaging time course sub-study of 30 patients, MVO had resolved by day 10 in 44% of affected patients, with persistence of IMH in 25% of these.² One potential explanation is the differing time-course of these pathologies with resolution of MVO in the presence of persistent IMH not disclosed by imaging at a single time-point up to 7 days. Imaging artefact may also be relevant. A small amount of MVO may not be visible within a zone of late gadolinium enhancement imaging and T2* artefact occurs at a tissue–air interface such as the infero-lateral wall of the left ventricle which may be mistaken for haemorrhage.

Therefore, IMH represents a target for preventive therapy, however, aside from timely reperfusion, there are no specific treatments for this problem. Favourable results in preclinical studies have not translated when assessed in patients.¹⁴ Randomized controlled clinical trials of novel therapeutic approaches designed to reduce the extent and severity of infarction, including novel cardioprotective interventions such as intra-venous beta-blocker therapy before reperfusion (EARLY-BAMI),¹⁵ intravenous inhibitors of mitochondria-mediated reperfusion injury, i.e. cyclosporine (CIRCUS),¹⁶ TRO40303 (MITOCARE),¹⁷ post-ischaemic conditioning (DANAMI-3 iPOST),¹⁸ and deferred stenting (DANAMI-3-DEFER),¹⁹ have not proven beneficial and intra-coronary vasodilator therapy with adenosine was actually harmful (REFLO-STEMI).²⁰ A *post hoc* analysis of the Phase 2 METOCARD-CNIC trial²¹ indicated intravenous beta-blocker therapy might reduce the risk of MVO through inhibition of neutrophil recruitment and platelet activation. MVO is now identified as a therapeutic target in practice guidelines,²² but the gaps in evidence on the causes and treatment of IMH highlight the need for more research.

We have recently conducted a Phase 2 clinical trial of low dose adjunctive intracoronary fibrinolysis with alteplase in reperfused STEMI (ClinicalTrials.gov: NCT02257294). The clinical strategy involved identifying patients in whom initial coronary angiography identified occluded infarct-related artery and/or with a high thrombus burden. These characteristics place the participants at an increased risk of MVO. By targeting thrombus within the infarct-related artery and microcirculation with fibrinolytic therapy the aim was to restore microvascular blood flow at the earliest point after coronary reperfusion. On the other hand, the intervention has the potential to promote bleeding within the infarct zone and systemically. The risk of IMH was purposefully mitigated by selecting patients presenting with a comparatively short ischaemic time (<6 h) in whom radial artery access was used. The overall objective was to conduct a safety, efficacy

and mechanisms evaluation within the context of a trial that was sufficiently large to give definitive results.

In conclusion, given that failed myocardial reperfusion occurs in one in every two patients undergoing primary PCI for acute STEMI, and IMH is an independent driver of prognosis, can primary PCI really be considered successful when these eventualities routinely occur? We think not. We propose that successful primary PCI is redefined as restoration of normal coronary blood flow in the absence of MVO and IMH. However, until specific evidence-based treatments for MVO and IMH become available, routine imaging with CMR to assess for these pathologies cannot be justified on economic grounds, and clinicians should follow optimal guideline-directed management for their post-MI patients.

Funding

This work was supported by the British Heart Foundation (BHF) Centre of Research Excellence Award (RE/13/5/30177) and a research grant from the National Institute of Health Research Efficacy and Mechanism Evaluation Programme (12/170/45).

Conflict of interest: The University of Glasgow holds a research agreement with Siemens Healthcare.

References

- Huynh T, Perron S, O'Loughlin J, Joseph L, Labrecque M, Tu JV *et al.* Comparison of primary percutaneous coronary intervention and fibrinolytic therapy in ST-segment-elevation myocardial infarction: Bayesian hierarchical meta-analyses of randomized controlled trials and observational studies. *Circulation* 2009;**119**:3101–31.
- Carrick D, Haig C, Ahmed N, McEntegart M, Petrie MC, Eteiba H *et al.* Myocardial hemorrhage after acute reperfused ST-segment-elevation myocardial infarction: relation to microvascular obstruction and prognostic significance. *Circ Cardiovasc Imaging* 2016;**9**:e004148.
- Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. *Lancet* 2003;**361**:13–20.
- Carrick D, Haig C, Rauhalampi S, Ahmed N, Mordy I, McEntegart M *et al.* Prognostic significance of infarct core pathology revealed by quantitative non-contrast in comparison with contrast cardiac magnetic resonance imaging in reperfused ST-elevation myocardial infarction survivors. *Eur Heart J* 2016;**37**: 1044–59.
- Wu X, Mintz GS, Xu K, Lansky AJ, Witzenbichler B, Guagliumi G *et al.* The relationship between attenuated plaque identified by intravascular ultrasound and no-reflow after stenting in acute myocardial infarction: the HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trial. *JACC Cardiovasc Interv* 2011;**4**:495–502.
- Viehman GE, Ma XL, Lefer DJ, Lefer AM. Time course of endothelial dysfunction and myocardial injury during coronary arterial occlusion. *Am J Physiol* 1991;**261**: 874–81.
- Beek AM, Nijveldt R, van Rossum AC. Intramyocardial hemorrhage and microvascular obstruction after primary percutaneous coronary intervention. *Int J Cardiovasc Imaging* 2010;**26**:49–55.
- Van Kranenburg M, Magro M, Thiele H, de Waha S, Eitel I, Cochet A *et al.* Prognostic value of microvascular obstruction and infarct size, as measured by CMR in STEMI patients. *JACC Cardiovasc Imaging* 2014;**7**:930–9.
- Carberry J, Carrick D, Haig C, Ahmed N, Mordy I, McEntegart M *et al.* Persistent iron within the infarct core after ST-segment elevation myocardial infarction: implications for left ventricular remodeling and health outcomes. *JACC Cardiovasc Imaging* 2017; doi:10.1016/j.jcmg.2017.08.027.
- Mather AN, Fairbairn TA, Ball SG, Greenwood JP, Plein S. Reperfusion haemorrhage as determined by cardiovascular MRI is a predictor of adverse left ventricular remodelling and markers of late arrhythmic risk. *Heart* 2011;**97**:453–9.

11. Kumar A, Green JD, Sykes JM, Ephrat P, Carson JJ, Mitchell AJ *et al.* Detection and quantification of myocardial reperfusion hemorrhage using T2*-weighted CMR. *JACC Cardiovasc Imaging* 2011;**4**:1274–83.
12. Reinstadler SJ, Stiermaier T, Reindl M, Feistritz HJ, Fuernau G, Eitel C *et al.* Intramyocardial hemorrhage and prognosis after ST-elevation myocardial infarction. *Eur Heart J Cardiovasc Imaging* 2019;**20**:138–46.
13. Eitel I, Kubusch K, Strohm O, Desch SD, Mikami Y, de Waha S *et al.* Prognostic value and determinants of a hypointense infarct core in T2-weighted cardiac magnetic resonance in acute reperfused ST-elevation-myocardial infarction. *Circ Cardiovasc Imaging* 2011;**4**:354–62.
14. Hausenloy DJ, Botker HE, Engstrom T, Erlinge D, Heusch G, Ibanez B *et al.* Targeting reperfusion injury in patients with ST-segment elevation myocardial infarction: trials and tribulations. *Eur Heart J* 2017;**38**:935–41.
15. Roolvink V, Ibanez B, Ottervanger JP, Pizarro G, van Royen N, Mateos A *et al.* Early intravenous beta-blockers in patients with ST-segment elevation myocardial infarction before primary percutaneous coronary intervention. *J Am Coll Cardiol* 2016;**67**:2705–15.
16. Cung TT, Morel O, Cayla G, Rioufol G, Garcia-Dorado D, Angoulvant D *et al.* Cyclosporine before PCI in patients with acute myocardial infarction. *N Engl J Med* 2015;**373**:1021–31.
17. Atar D, Arheden H, Berdeaux A, Bonnet JL, Carlsson M, Clemmensen P *et al.* Effect of intravenous TRO40303 as an adjunct to primary percutaneous coronary intervention for acute ST-elevation myocardial infarction: MITOCARE study results. *Eur Heart J* 2015;**36**:112–9.
18. Engstrom T, Kelbaek H, Helqvist S, Hofsten DE, Klovgaard L, Clemmensen P *et al.* Effect of ischemic postconditioning during primary percutaneous coronary intervention for patients with ST-segment elevation myocardial infarction: a randomized clinical trial. *JAMA Cardiol* 2017;**2**:490–7.
19. Kelbaek H, Hofsten DE, Kober L, Helqvist S, Klovgaard L, Holmvang L *et al.* Deferred versus conventional stent implantation in patients with ST-segment elevation myocardial infarction (DANAMI 3-DEFER): an open-label, randomised controlled trial. *Lancet* 2016;**387**:2199–206.
20. Nazir SA, McCann GP, Greenwood JP, Kunadian V, Khan JN, Mahmoud IZ *et al.* Strategies to attenuate micro-vascular obstruction during P-PCI: the randomized reperfusion facilitated by local adjunctive therapy in ST-elevation myocardial infarction trial. *Eur Heart J* 2016;**37**:1910–9.
21. Ibanez B, Macaya C, Sanchez-Brunete V, Pizarro G, Fernandez-Friera L, Mateos A *et al.* Effect of early metoprolol on infarct size in ST-segment-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: the effect of metoprolol in cardioprotection during an acute myocardial infarction (METOCARD-CNIC) trial. *Circulation* 2013;**128**:1495–503.
20. Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H *et al.* 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). *Eur Heart J* 2018;**39**:119–77.